News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,805 Results
Type
Article (13809)
Company Profile (101)
Press Release (251895)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88069)
Career Advice (465)
Deals (15346)
Drug Delivery (67)
Drug Development (36609)
Employer Resources (49)
FDA (6298)
Job Trends (6201)
News (150259)
Policy (14044)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (33)
Alliances (23230)
ALS (36)
Alzheimer's disease (393)
Antibody-drug conjugate (ADC) (41)
Approvals (6334)
Artificial intelligence (107)
Autoimmune disease (9)
Automation (4)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (21)
Brain cancer (16)
Breast cancer (79)
Cancer (618)
Cardiovascular disease (72)
Career advice (408)
Career pathing (12)
CAR-T (22)
Cell therapy (88)
Cervical cancer (4)
Clinical research (30932)
Collaboration (345)
Compensation (155)
Complete response letters (17)
COVID-19 (757)
CRISPR (20)
C-suite (124)
Cystic fibrosis (37)
Data (640)
Denatured (15)
Depression (9)
Diabetes (81)
Diagnostics (1319)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (65)
Drug shortages (12)
Duchenne muscular dystrophy (36)
Earnings (32161)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37524)
Executive appointments (392)
FDA (6722)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (215)
Gene editing (38)
Generative AI (9)
Gene therapy (101)
GLP-1 (349)
Government (1299)
Grass and pollen (3)
Guidances (16)
Healthcare (3564)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (14)
Infectious disease (792)
Inflammatory bowel disease (55)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (47)
Interviews (59)
IPO (5880)
IRA (29)
Job creations (2051)
Job search strategy (373)
Kidney cancer (6)
Labor market (12)
Layoffs (180)
Leadership (3)
Legal (3433)
Liver cancer (19)
Lung cancer (82)
Lymphoma (55)
Machine learning (1)
Management (16)
Manufacturing (160)
MASH (32)
Medical device (1276)
Medtech (1278)
Mergers & acquisitions (9674)
Metabolic disorders (262)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (8)
Neuroscience (579)
NextGen: Class of 2025 (1586)
Non-profit (593)
Northern California (713)
Now hiring (8)
Obesity (150)
Opinion (119)
Ovarian cancer (21)
Pain (51)
Pancreatic cancer (14)
Parkinson's disease (47)
Partnered (7)
Patents (117)
Patient recruitment (29)
Peanut (10)
People (28960)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8048)
Phase II (13088)
Phase III (11744)
Pipeline (446)
Policy (72)
Postmarket research (1401)
Preclinical (3222)
Press Release (25)
Prostate cancer (46)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (168)
Real estate (2637)
Recruiting (17)
Regulatory (10124)
Reports (14)
Research institute (565)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (37)
Series B (13)
Service/supplier (3)
Sickle cell disease (32)
Southern California (728)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1629)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (26)
The Weekly (30)
United States (7272)
Vaccines (153)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (3)
Date
Today (25)
Last 7 days (214)
Last 30 days (882)
Last 365 days (11748)
2025 (3650)
2024 (12503)
2023 (14249)
2022 (19558)
2021 (20071)
2020 (19034)
2019 (14885)
2018 (11714)
2017 (13889)
2016 (13130)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (55)
Arkansas (3)
Asia (20137)
Australia (2615)
California (1733)
Canada (913)
China (239)
Colorado (70)
Connecticut (68)
Delaware (56)
Europe (39473)
Florida (329)
Georgia (38)
Idaho (9)
Illinois (197)
India (16)
Indiana (135)
Iowa (1)
Japan (93)
Kansas (57)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (258)
Massachusetts (1498)
Michigan (30)
Minnesota (95)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (770)
New Mexico (7)
New York (513)
North Carolina (396)
North Dakota (2)
Northern California (713)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (446)
Puerto Rico (8)
Rhode Island (10)
South America (502)
South Carolina (2)
Southern California (728)
Tennessee (34)
Texas (233)
Utah (34)
Virginia (75)
Washington D.C. (31)
Washington State (120)
Wisconsin (16)
265,805 Results for "asieris pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Asieris Pharmaceuticals Releases 2024 Annual Report, with Revenue Exceeding RMB 200M in 1st Year of Commercialization and Innovative Portfolio Accelerating Toward Launch
April 21, 2025
·
9 min read
Business
ReviR Therapeutics Reaches Milestone in Novel Splicing Therapy Development in Collaboration with Asieris Pharmaceuticals
ReviR Therapeutics and Asieris Pharmaceuticals, a global biopharmaceutical leader in the discovery, development, and commercialization of innovative drugs for genitourinary tumors and related diseases, announced a milestone was reached today in their ongoing collaboration.
June 17, 2024
·
4 min read
Business
Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women’s Health Business Unit, Accelerating Strategic Expansion
Asieris Pharmaceuticals has announced its set-up of the Women’s Health Business Unit for commercialization.
January 8, 2024
·
6 min read
Press Releases
Asieris and CDC Sign Investigational Product Supply Agreement for APL-1202 in Free-Living Amoeba Infections Treatment under Expanded Access Investigational New Drug Program
January 6, 2025
·
3 min read
Drug Development
Asieris Pharmaceuticals Unveils 2023 Annual Report, Core Product APL-1702 Succeeds in Global Phase III Clinical Trials, APL-1706 obtains NDA acceptance domestically, Specialty Commercial Team Generates Sustained Revenue Streams
Asieris Pharmaceuticals released its 2023 Annual Report, revealing impressive outcomes achieved through its specialty pharma strategy, which has facilitated rapid progress in clinical development, early research, and commercialization.
April 17, 2024
·
9 min read
Drug Development
APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia
Asieris Pharmaceuticals announced that its product, APL-2301, used for the treatment of Acinetobacter baumannii infections, was approved for Phase I clinical trials in Australia.
December 24, 2023
·
2 min read
Drug Development
Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting
Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has communicated the Phase III clinical study results for its non-surgical treatment candidate for cervical high-grade squamous intraepithelial lesions Cevira®.
March 18, 2024
·
5 min read
Policy
Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China
Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals communicated that the National Medical Products Administration accepted the new drug application for Hexvix® in China.
November 29, 2023
·
5 min read
Press Releases
Asieris Pharmaceuticals Releases 2024 Semi-Annual Report, Highlighting Steady Progress in Launching Blockbuster Product for Precancerous Cervical Lesions and Continued Strengthening of Commercial Revenue Generation Capabilities
August 28, 2024
·
7 min read
Drug Development
Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, a Bladder Cancer Diagnosis and Management Drug, at the 2024 ASCO-GU
Asieris Pharmaceuticals announced the release of Phase III clinical trial data and real-world study data for APL-1706, a bladder cancer diagnosis and management drug, at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium in the form of a poster presentation.
January 29, 2024
·
3 min read
1 of 26,581
Next
